Helping NET Cancer patients get a timely diagnosis,
the best care and ultimately a cure
If you don’t suspect it you can’t detect it
84% of NET patients
Their needs for information about treatment
options were not met at the time of diagnosis.
58% of NET patients are
diagnosed at an advanced stage
How Can I Help?
First World NET Forum 2020 on 10 – 11 March in Barcelona – Convened by ENETS in Partnership with the NET Medical Societies Around the World and INCA
INCA is proud to be associated with the first ever World NET Scientific Forum to take place next year at the annual European Neuroendocrine Tumor Society (ENETS) Conference in March in Barcelona. INCA President, Simone Leyden has been actively involved in the Steering...read more
The first results of the Phase II study of 177Lu-Octreotate peptide receptor radionuclide therapy +/- capecitabine, temozolomide for midgut neuroendocrine tumours (mNETs) has been accepted as part of the Rapid Results section and as a poster at ASCO GI 2020 to be held...read more
COMPETE is led as an international, prospective, randomized, controlled, open-label, multicenter phase III study. This means, that during the study new data will be collected (prospective), that results in patients receiving the new treatment are compared to a control...read more